CSMG Technologies Announces Breakthrough Tissue Welding for Human Laryngectomy and Chondrectomy Procedures.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc. (OTCBB: CTUM), a technology management company focused on commercializing human live tissue bonding devices, announced breakthrough laryngectomy and chondrectomy procedures have successfully been completed using the company's platform live biological tissue welding/bonding technology.

Dr. Rustem A. Abizov, at the ENT department of the Kiev Regional Clinical Hospital, during May through November, 2006, utilized electro welding/bonding technology devices from the company's subsidiary, Live Tissue Connect, to surgical treat patients suffering from the larynx cancer. Thirty-two patients with larynx cancer of the II-III degree, 25 laryngectomies and seven chondrectomies were completed. Dr. Abizoy is holder of the Otorinolaryngology Chair at the Kiev Medical Academy for Postgraduate Studies.

Abizov said, "Using the tissue welding technology for laryngectomy and chondrectomy resection has these main, important advantages: 1. reduced time of surgical interventions is by1.5-2 times, 2. less time for hemostasis, 3. less time for the patient under anesthesia, 4. less blood loss (no more than 50 ml of blood of blood loss in welding surgeries as opposed to approximately four times that amount or approximately 200 ml in conventional laryngectomies), 5. the technology allows for both separation and reconnection of biological tissue (to form the pharyngoesophageal anastomosis), and, lastly, 6. considerably reduced amount of sutural materials needed for such surgical interventions.

"In all patients during the postoperative period were without complications and the wounds healed by primary intention. These patients are being followed-up and examined once a month," added Dr. Abizov.

Donald S. Robbins, president and CEO of CSMG, said, "It is rewarding to note the consistent advantages over conventional wound closing methods that the tissue welding technology produces when considering the wide range of procedures we are able to perform. Especially impressive is the ability to successfully apply the technology to such difficult and tedious procedures as Laryngectomy and Chondrectomy. Both surgeries are recognized for problems of intense bleeding and in areas where nerve damage can easily occur. We are continually expanding our procedure capabilities, thus increasing our licensing and marketing capabilities."

Mr. Frank D'Amelio, a seasoned medical device executive with substantial hands-on medical device development and management experience, and consultant who's leading LTC during this period remarked, "We've got a lot of hard work ahead of us. We're now focusing on comparative clinical testing, FDA submissions and lining up manufacturing."

LTC expects to complete a U.S. and European regulatory device for duct and vessel sealing meeting FDA and European CE Mark standards, respectively, and file for approval of the device with the two regulatory entities early next year.

CSMG owns the technology and exclusive world rights to the medical device through Live Tissue Connect, Inc. (LTC), a subsidiary corporation formed for the development and exploitation of the platform technology.

About CSMG Technologies' Tissue Welding/Bonding Technology

The Live Tissue Connect tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues.

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 6,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.